Search Results

You are looking at 21 - 30 of 654 items for :

  • "immunotherapy" x
  • Refine by Access: All x
Clear All
Full access

Updates on the Management of Immunotherapy-Related Toxicities

Presented by: Marianne Davies, Jordan McPherson, and John A. Thompson

Immunotherapy has emerged as the fourth pillar of cancer treatment, beyond surgery, radiation, and chemotherapy, offering new hope and improved outcomes for patients. However, with its increasing use, managing the potential side effects and

Full access

Point: Interferon-α for Adjuvant Therapy for Melanoma Patients

Michael S. Sabel and Vernon K. Sondak

; 25 : 1 – 6 . 44 Morton DL Hsueh EC Essner R . Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes . Ann Surg

Full access

Pancreatitis and Hyperlipasemia in the Setting of Immune Checkpoint Inhibitor Therapy

Matthew J. Townsend, Mofei Liu, Anita Giobbie-Hurder, Jordan S. Sack, Nicole R. LeBoeuf, F. Stephen Hodi, Julia McNabb-Baltar, and Shilpa Grover

Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Management of Immunotherapy-Related Toxicities highlight the need to consider alternative causes of hyperlipasemia or hyperamylasemia (of any severity), 8 the proportion of pancreatic injury

Full access

Hypophysitis and Secondary Adrenal Insufficiency From Immune Checkpoint Inhibitors: Diagnostic Challenges and Link With Survival

Jake Johnson, Whitney Goldner, Duaa Abdallah, Fang Qiu, Apar Kishor Ganti, and Anupam Kotwal

between December 1, 2012, and December 31, 2019. Hypophysitis was defined consistent with previous studies 2 , 8 , 18 , 19 and the 2022 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Management of Immunotherapy-Related Toxicities 12

Full access

Early Liver Specialist Consultation is Associated With Faster Biochemical Resolution of Severe Immune Checkpoint Inhibitor–Induced Hepatitis

Michael Li, Danny Wong, Jordan S. Sack, Alexander S. Vogel, F. Stephen Hodi, Lawrence Fong, Jennifer C. Lai, Shilpa Grover, and Stephen D. Zucker

previously treated with sorafenib: the CheckMate 040 randomized clinical trial . JAMA Oncol 2020 ; 6 : e204564 . 33001135 14. Brahmer JR , Abu-Sbeih H , Ascierto PA , Society for Immunotherapy of Cancer (SITC) clinical practice

Full access

Current Evidence-Based Systemic Therapy for Advanced and Recurrent Endometrial Cancer

Sushmita Gordhandas, William A. Zammarrelli III, Eric V. Rios-Doria, Angela K. Green, and Vicky Makker

induction with type I and II interferons. Higher TMB and greater infiltration of CD68+ macrophages in EC have been proposed as potential mechanisms of response to immunotherapy. 36 , 37 Although predictive of immune checkpoint response in other cancers, PD

Full access

CLO24-069: Pneumonitis Incidences in Metastatic Non–Small Cell Lung Cancer on Immunotherapy: A Systematic Review and Meta-Analysis

Sakditad Saowapa, Natchaya Polpichai, Pharit Siladech, Chalothorn Wannaphut, Manasawee Tanariyakul, Phuuwadith Wattanachayakul, and Pakin Lalitnithi

immunotherapy. Immunotherapy (checkpoint inhibitors utilization) boosts the immune system to recognize and destroy cancer cells. However, it is often associated with immune-related complications such as pneumonitis. Objective: The present review aims to

Full access

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Featured Updates to the NCCN Guidelines

John A. Thompson, Bryan J. Schneider, Julie Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew Frigault, Benjamin H. Kaffenberger, Matthew Lunning, Suzanne McGettigan, Jordan McPherson, Nisha A. Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan Oluwole, Sandip P. Patel, Nathan Pennell, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Yinghong Wang, Ryan M. Weight, Alyse Johnson-Chilla, Griselda Zuccarino-Catania, and Anita Engh

able to: Integrate into professional practice the updates to the NCCN Guidelines for Management of Immunotherapy-Related Toxicities Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Management of

Full access

An Expanding Role for Immunotherapy in Colorectal Cancer

Katherine M. Bever and Dung T. Le

benefits. 4 , 5 Immunotherapy holds promise as a more targeted, potentially less toxic therapy, and the so-called checkpoint inhibitors (CPIs) have recently received regulatory approval in multiple cancers, including melanoma and lung, kidney, bladder

Full access

Emerging Treatment Options for Acute Lymphoblastic Leukemia: Focus on CAR T-Cell Therapy

Patrick A. Brown and Bijal Shah

with these new immunotherapies. “CAR T-cell therapy has transformed the therapeutic options for patients with ALL, but there is still more work ahead that needs to be completed.” Overview of ALL ALL comprises 80% of childhood leukemia and 15% to